All In Biotech

Drug Trial Radar · NCT05420961

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)

A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older

Last checked: Nov 19, 2026Latest source record: Oct 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 717 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

717

Actual

Start

Jul 12, 2022

Primary completion

May 16, 2023

Study completion May 16, 2023

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jun 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This a study of V116 in adults ≥50 years of age who previously received a pneumococcal vaccination ≥1 year before enrollment. The primary objectives of this study are to evaluate the safety, tolerability, and immunogenicity of V116.

Conditions

  • Pneumonia, Pneumococcal

Interventions

  • V116Biological

    Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution

  • PCV15Biological

    Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F, and 4 μg of 6B in each 0.5 mL sterile suspension

  • PPSV23Biological

    Pneumococcal 23-valent vaccine with 25 μg of each of the PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Solicited Injection-site Adverse Events (AEs)Time frame: Up to 5 days post-vaccination
  2. Percentage of Participants With Solicited Systemic AEsTime frame: Up to 5 days post-vaccination
  3. Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs)Time frame: Up to ~180 days
  4. Geometric Mean Titer (GMT) of Serotype-specific Opsonophagocytic Activity (OPA)Time frame: 30 Days post-vaccination

Locations

51 sites in 9 countries. Site status is shown where the registry gives one.

  • Central Research Associates ( Site 0024)

    Birmingham, Alabama

  • Lenzmeier Family Medicine/CCT Research ( Site 0008)

    Glendale, Arizona

  • Fiel Family and Sports Medicine, PC/CCT Research ( Site 0006)

    Tempe, Arizona

  • Southland Clinical Research Center ( Site 0026)

    Fountain Valley, California

  • Diablo Clinical Research, Inc. ( Site 0019)

    Walnut Creek, California

  • Alliance for Multispecialty Research, LLC ( Site 0020)

    Coral Gables, Florida

  • Indago Research & Health Center, Inc ( Site 0005)

    Hialeah, Florida

  • Advanced Medical Research Institute ( Site 0018)

    Miami, Florida

  • Solaris Clinical Research ( Site 0025)

    Meridian, Idaho

  • Centennial Medical Group ( Site 0002)

    Elkridge, Maryland

  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division ( Site 0016)

    Troy, Michigan

  • Meridian Clinical Research, LLC ( Site 0009)

    Norfolk, Nebraska

  • Advanced Medical Research ( Site 0001)

    Maumee, Ohio

  • University of Texas Medical Branch-Sealy Institute for Vaccine Sciences Clinical Trials Program ( Si

    Galveston, Texas

  • Health Research of Hampton Roads, Inc. ( Site 0003)

    Newport News, Virginia

  • Hamilton Medical Research Group ( Site 0114)

    Hamilton, Ontario, Canada

  • Milestone Research Inc. ( Site 0104)

    London, Ontario, Canada

  • Manna Research Mirabel ( Site 0109)

    Mirabel, Quebec, Canada

  • CHU de Québec-Université Laval-Équipe de recherche en vaccination ( Site 0120)

    Québec, Quebec, Canada

  • Diex Recherche Sherbrooke Inc. ( Site 0101)

    Sherbrooke, Quebec, Canada

  • Hopitaux Universitaires Paris Centre-Hopital Cochin ( Site 0203)

    Paris, France

  • CHU Bordeaux Haut-Leveque ( Site 0202)

    Pessac, Aquitaine, France

  • CHRU de Brest ( Site 0200)

    Brest, Finistere, France

  • centre hospitalier lyon sud ( Site 0204)

    Pierre-Bénite, Rhone, France

  • Rambam Health Care Campus ( Site 0303)

    Haifa, Israel

  • Maccabi Health Services - Holon ( Site 0305)

    Holon, Israel

  • Maccabi Healthcare Services ( Site 0306)

    Jerusalem, Israel

  • Hadassah Medical Center-Clinical Reaserch Unit ( Site 0300)

    Jerusalem, Israel

  • Meir Medical Center ( Site 0301)

    Kfar Saba, Israel

  • Sheba Medical Center-Early Phase Clinical Trials Unit ( Site 0304)

    Ramat Gan, Israel

  • Clalit Health Services - Sakhnin Community Clinic-Research Unit ( Site 0302)

    Sakhnin, Israel

  • Azienda Ospedaliero Universitaria Policlinico Riuniti di Foggia ( Site 0405)

    Foggia, Italy

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico ( Site 0400)

    Milan, Lombardy, Italy

  • Ospedale San Raffaele ( Site 0403)

    Milan, Lombardy, Italy

  • A.O.U. Policlinico Paolo Giaccone ( Site 0402)

    Palermo, Sicily, Italy

  • PS Clinic ( Site 0700)

    Fukuoka, Japan

  • Nishikumamoto Hospital ( Site 0701)

    Kumamoto, Japan

  • The Catholic University of Korea, Eunpyeong St. Mary's Hospital ( Site 0752)

    Seoul, South Korea

  • The Catholic Univ. of Korea Seoul St. Mary's Hospital ( Site 0753)

    Seoul, South Korea

  • Hallym University Kangnam Sacred Heart Hospital-Internal Medicine ( Site 0754)

    Seoul, South Korea

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.